Michele Baccarani

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
  2. ncbi Response definitions and European Leukemianet Management recommendations
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Best Pract Res Clin Haematol 22:331-41. 2009
  3. ncbi Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 27:6041-51. 2009
  4. ncbi Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 117:1010-8. 2011
  5. ncbi Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Blood 114:5191-200. 2009
  6. ncbi Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma
    Enrico Derenzini
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 113:2496-503. 2008
  7. ncbi ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    , University of Bologna, Via Massarenti 9-40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
  8. ncbi Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
  9. ncbi Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
  10. ncbi Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
    Michele Cavo
    Dipartimento di Ematologia e Scienze Oncologiche Seràgnoli, Istituto di Ematologia Seragnoli, Universita di Bologna, Bologna, Italy
    J Clin Oncol 27:5001-7. 2009

Detail Information

Publications97

  1. ncbi The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
    ..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate...
  2. ncbi Response definitions and European Leukemianet Management recommendations
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Best Pract Res Clin Haematol 22:331-41. 2009
    ..A provisional definition of the response to second-generation TKIs second line is provided...
  3. ncbi Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 27:6041-51. 2009
    ....
  4. ncbi Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 117:1010-8. 2011
    ....
  5. ncbi Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Blood 114:5191-200. 2009
    ..Moreover, leukemic CD34(-) cells survived exposure to BCR-ABL inhibitors in vivo. Thus, we identified a novel CD34(-) leukemic stem cell subset in CML with peculiar molecular and functional characteristics...
  6. ncbi Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma
    Enrico Derenzini
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 113:2496-503. 2008
    ....
  7. ncbi ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    , University of Bologna, Via Massarenti 9-40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  8. ncbi Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
    ..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient...
  9. ncbi Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  10. ncbi Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
    Michele Cavo
    Dipartimento di Ematologia e Scienze Oncologiche Seràgnoli, Istituto di Ematologia Seragnoli, Universita di Bologna, Bologna, Italy
    J Clin Oncol 27:5001-7. 2009
    ..To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM)...
  11. ncbi Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  12. ncbi Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Lancet Oncol 9:352-8. 2008
    ....
  13. ncbi IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report
    Giovanni Martinelli
    Molecular Biology Unit, Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    J Clin Oncol 27:5202-7. 2009
    ....
  14. ncbi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
    ..This study investigated the role of immunohistochemical discrimination between GCB and ABC&NC-DLBCL subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach...
  15. ncbi Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012
    ..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy...
  16. ncbi Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Ann Hematol 91:419-26. 2012
    ..TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8%)...
  17. ncbi Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    , University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ....
  18. ncbi Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009
    ..R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL...
  19. ncbi Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  20. ncbi Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Blood 108:1809-20. 2006
    ..The importance of regular monitoring at experienced centers was highlighted...
  21. ncbi Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
    ..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases...
  22. ncbi Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging
    Alessandro Isidori
    Institute of Hematology and Medical Oncology, L and A Seragnoli, University of Bologna, Bologna, Italy
    Biol Blood Marrow Transplant 13:1224-32. 2007
    ..However, the purging potential of positive selection of CD133(+) cells is not adequate to achieve tumor-free autografts...
  23. ncbi Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy
    Cancer 100:2190-4. 2004
    ....
  24. ncbi Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
    ..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors...
  25. ncbi Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Blood 118:5989-95. 2011
    ..PET/CT involvement at diagnosis, after novel agent-based induction and subsequent ASCT is a reliable predictor of prognosis in MM patients. This study is registered at www.clinicaltrials.gov as NTC01341262...
  26. ncbi Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    , University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05)...
  27. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  28. ncbi VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly
    Mariapaola Fina
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 48:2167-71. 2007
    ..Three CRs relapsed within 12 months from the completion of treatment. Clinical and hematological toxicity was moderate. This regimen was effective in inducing a good remission rate with moderate toxic effects in elderly DLBCL patients...
  29. ncbi Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors
    Mario Arpinati
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Biol Blood Marrow Transplant 13:228-34. 2007
    ..In conclusion, pretransplantation recipient monocyte levels are relevant to the development of GVHD in HSCT from related donors...
  30. ncbi A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 112:856-62. 2008
    ....
  31. ncbi Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
    Antonio Curti
    Institute of Hematology, Department of Hematology and Oncological Sciences L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Blood 118:3273-9. 2011
    ..In conclusion, infusion of purified NK cells is feasible in elderly patients with high-risk acute myeloid leukemia. This trial was registered at www.clinicaltrial.gov as NCT00799799...
  32. ncbi Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency
    Patrizia Tosi
    Institute of Hematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Biol Blood Marrow Transplant 16:1115-21. 2010
    ..Given the relationship between recovery of renal function and response to induction treatment, more intensive Thal + bortezomib regimens could be explored to rescue higher numbers of patients...
  33. ncbi Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571
    Lucia Mazzacurati
    , University of Bologna, Medical School, Bologna, Italy
    Hematol J 5:168-77. 2004
    ..In CML, they might further enhance the proliferative advantage and genomic instability of clonal myeloid progenitors featuring a class of poor prognosis patients eventually resistant to STI571...
  34. ncbi First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
    ..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients...
  35. ncbi Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138, Bologna, Italy
    Blood 106:35-9. 2005
    ..Thal-Dex may be considered an effective and relatively well-tolerated oral alternative to the more complex VAD regimen as front-line therapy for MM patients who are candidates for subsequent autologous transplantation...
  36. ncbi Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Blood 104:4245-51. 2004
    ..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies...
  37. ncbi Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:291-5. 2007
    ..The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment...
  38. ncbi Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease
    Mario Arpinati
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Transplantation 85:1826-32. 2008
    ..Based on experimental models, chronic graft-versus-host disease (cGVHD) may depend on activated donor antigen-presenting cells presenting host antigens to donor T cells...
  39. ncbi Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
    ..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926...
  40. ncbi High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Leuk Lymphoma 45:321-6. 2004
    ..Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further...
  41. ncbi Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
    Francesca Palandri
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1792-6. 2008
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  42. ncbi Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    , University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..It may therefore potentially be a valuable tool for regular, large-scale testing of patients undergoing Imatinib treatment...
  43. ncbi Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission
    Michele Malagola
    , University of Bologna, Italy
    Haematologica 89:ECR25. 2004
  44. ncbi Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    , University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progression-free and overall survival...
  45. ncbi Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients
    Alessandro Isidori
    , University of Bologna, Italy
    Haematologica 90:225-31. 2005
    ..INTERPRETATION AND CONCLUSIONS: Our results show that pegfilgrastim as an adjunct to chemotherapy is a predictable and highly effective mobilization regimen in pretreated lymphoma patients...
  46. ncbi Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma Leuk 11:462-6. 2011
    ..Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL...
  47. ncbi Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice
    Valentina Salvestrini
    Department of Hematology and Oncological Sciences, L and A Seragnoli, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Blood 119:217-26. 2012
    ..We conclude that, unlike normal cells, P2R signaling inhibits leukemic cells and therefore its pharmacologic modulation may represent a novel therapeutic strategy...
  48. ncbi Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  49. ncbi Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients
    Cinzia Pellegrini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Lymphoma Myeloma Leuk 11:321-5. 2011
    ..We performed a retrospective investigation to assess the efficacy of chemotherapy and rituximab as front-line treatment for primary bone lymphoma (PBL)...
  50. ncbi Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
    Antonio Curti
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 139:415-24. 2007
    ..In conclusion, sc injections of cryopreserved Id-pulsed DCs were safe and, in contrast with intravenous administrations, induced anti-MM T-cell responses...
  51. ncbi Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
    Giulia Marzocchi
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 117:6793-800. 2011
    ..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  52. ncbi Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
    Gianantonio Rosti
    , University of Bologna, Italy
    Blood 103:2284-90. 2004
    ..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet...
  53. ncbi Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 27:1781-7. 2009
    ..However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission...
  54. ncbi The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
    ..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...
  55. ncbi First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138, Bologna, Italy
    Haematologica 89:826-31. 2004
    ....
  56. ncbi Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
    Antonio Curti
    , University of Bologna, Bologna, Italy
    Leuk Lymphoma 45:1419-28. 2004
    ..Based on these results, a DCs-based phase II trial of anti-Id vaccination with VDJ-derived HLA class I-restricted peptides and KLH is underway for lymphoma patients...
  57. ncbi Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  58. ncbi Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome
    Giovanni Martinelli
    , University of Bologna, Italy
    Haematologica 89:236-7. 2004
  59. ncbi Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 114:2168-71. 2009
    ....
  60. ncbi Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Cancer Res 15:1059-63. 2009
    ..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib...
  61. ncbi Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy
    Clin Cancer Res 16:3998-4004. 2010
    ....
  62. ncbi Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leuke
    Ilaria Iacobucci
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 114:2159-67. 2009
    ....
  63. ncbi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010
    ....
  64. ncbi Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
    Simona Soverini
    , University of Bologna, Italy
    Lancet Oncol 8:273-4. 2007
  65. ncbi The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration
    Lara Rossi
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, and Stem Cell Research Center, S Orsola Malpighi Hospital, Italy
    Blood 109:533-42. 2007
    ..Our data suggest that UTP may physiologically modulate the homing of HSCs to the BM, in concert with CXCL12, via the activation of converging signaling pathways between CXCR4 and P2Y receptors, involving Galphai proteins and RhoGTPases...
  66. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  67. ncbi Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation
    Mario Arpinati
    Research Center for Transplant Immunology, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Biol Blood Marrow Transplant 10:106-15. 2004
    ..These results will prompt new studies addressing whether DC reconstitution correlates with immunity against infectious agents or with graft-versus-tumor reactions after PB stem cell allotransplantation...
  68. ncbi Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
    ..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited...
  69. ncbi Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma
    Patrizia Tosi
    Institute of Hematology and Medical Oncology, Seragnoli University of Bologna, Bologna, Italy
    Eur J Haematol 74:212-6. 2005
    ..This latter therapeutic approach has risen the concern of side-effects of long-term therapy with this drug...
  70. ncbi Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:731-3. 2004
    ..In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL...
  71. ncbi Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation
    Paolo Castellucci
    Nuclear Medicine Department, S. Orsola-Malpighi Hospital, Bologna, Italy
    Nucl Med Commun 26:689-94. 2005
    ..For the same purpose, it is reasonable to think that the use of hybrid PET/CT tomographs could also play an important role in helping to identify non-tumoural FDG focal uptake...
  72. ncbi Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant
    Benedetta Urbini
    Research Center for Transplant Immunology, , University of Bologna, Bologna, Italy
    Exp Hematol 31:959-65. 2003
    ..Higher doses of CD34(+) cells in PBSC, but not in marrow, seem to adversely affect survival after transplant...
  73. ncbi Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
    Simona Soverini
    , University of Bologna, Via Massarenti 9-40138 Bologna, Italy
    Blood 102:1588-94. 2003
    ..055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation...
  74. ncbi Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  75. ncbi Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  76. ncbi Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline
    Marta Stanzani
    Institute of Hematology and Clinical Oncology Lorenzo e Ariosto Serágnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    J Med Microbiol 56:1692-5. 2007
    ..The patient was successfully treated by prolonged administration of a full dose of colistin and tigecycline, and surgical curettage with the positioning of resorbable calcium sulfate pellets loaded with colistin...
  77. ncbi Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    , University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...
  78. ncbi Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR37. 2003
  79. ncbi 18F-FDG PET early after radiotherapy in lymphoma patients
    Paolo Castellucci
    U.O. Medicina Nucleare, PET Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
    Cancer Biother Radiopharm 19:606-12. 2004
    ..CONCLUSION: Our data indicates that the rate of postactinic PET inflammatory alterations in lymphoma patients is not very high and appear to be not strictly linked to the elapsed time since the end of RT treatment...
  80. ncbi Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
    Marina Ratta
    Institute of Hematology and Medical Oncology, Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy
    Blood 100:230-7. 2002
    ..This brings into question the advisability of using PBDCs as antigen carriers for immunotherapy trials in MM. The results also suggest a novel mechanism whereby myeloma cells escape immune recognition...
  81. ncbi Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 113:4497-504. 2009
    ..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488...
  82. ncbi Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  83. ncbi Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade
    Mario Arpinati
    Research Center for Transplant Immunology, , University of Bologna, Bologna, Italy
    Exp Hematol 31:31-8. 2003
    ..Therefore, our data allow design of in vivo studies aimed at achieving T-cell tolerance across HLA barriers by using purified CD34(+) cells and costimulatory blockade...
  84. ncbi Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination
    Maria R Motta
    Institute of Haematology and Medical Oncology, , University of Bologna, Bologna, Italy
    Br J Haematol 121:240-50. 2003
    ..The recovery of thawed, viable DC was 78 +/- 10%. Finally, interferon-alpha-2b was at least as efficient as IL-4 in inducing the differentiation of mature, functional DC from monocytes...
  85. ncbi p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase
    Gianluca Brusa
    , University of Bologna Medical School, Bologna, Italy
    Haematologica 88:622-30. 2003
    ..Deregulated activity of the cyclin B1-cdc2 complex may be involved in the loss of temporal co-ordination of mitotic events and further free the barrier to genomic instability of CML clonal myeloid progenitors lacking p53...
  86. ncbi Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B
    Marta Stanzani
    Institute of Hematology and Clinical Oncology Seràgnoli, University of Bologna, Italy
    J Infect 53:e243-6. 2006
    ..We report a case of disseminated Fusariosis in a severe immunocompromised patient after allo-SCT that responded to treatment with the early combination of intravenous voriconazole and liposomal amphotericin B...
  87. ncbi The therapeutic role of dendritic cells in cancer immunotherapy
    Roberto M Lemoli
    , University of Bologna, Italy
    Haematologica 87:62-6. 2002
  88. ncbi The cytogenetic response as a surrogate marker of survival
    Gianantonio Rosti
    , Bologna, Italy
    Semin Hematol 40:56-61. 2003
    ..Low-risk patients survive longer than non-low-risk patients given the same CgR. Preliminary results from studies with imatinib are superior and CgR remains an important surrogate marker of survival in the imatinib era...
  89. ncbi Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells
    Roberto M Lemoli
    Istituto di Ematologia e Oncologia Medica L and A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 123:720-9. 2003
    ..Thus, our study indicated that CD34 expression on human PB stem cells was associated with haematopoietic activity, cell-cycle recruitment and downregulation of p27Kip1 in vitro and higher engraftment capacity in vivo...
  90. ncbi Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Haematologica 89:309-13. 2004
    ..Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years...
  91. ncbi The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
    Antonio Curti
    Department of Hematology and Oncological Sciences L and A Seràgnoli, University of Bologna and Stem Cell Research Center, Azienda Ospedaliero Universitaria Policlinico S Orsola Malpighi, Bologna, Italy
    Blood 113:2394-401. 2009
    ..In this review, the role of IDO in the induction of immunologic tolerance is addressed with a specific focus on its recently discovered effect on hematologic malignancies...
  92. ncbi Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
    ..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria...
  93. ncbi Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells
    Michela Aluigi
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Via Massarenti, 9, 40137 Bologna, Italy
    Stem Cells 24:454-61. 2006
    ..In conclusion, nucleofection is an efficient nonviral transfection technique for hMSCs, which then may be used as cellular vehicles for the delivery of biological agents...
  94. ncbi Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna
    Leuk Lymphoma 46:1449-54. 2005
    ..985; p = 0.049). Post-treatment hemoglobin values appear to provide a strong independent predictor of 5-year survival in elderly aggressive NHL, supporting the potential role of anemia correction in this group of patients...
  95. ncbi First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
    Patrizia Tosi
    Institute of Hematology and Medical Oncology L e A Seràgnoli Bologna University, Bologna, Italy
    Eur J Haematol 76:399-404. 2006
    ..The evaluation of biochemical markers of bone turnover could allow a dynamic evaluation of the effects of a given therapy on bone metabolism...
  96. ncbi Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters
    Nicola Vianelli
    Haematology and Oncology Institute L and A Seràgnoli, S Orsola Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna
    Haematologica 91:983-5. 2006
    ..Moreover, we observed a significant reduction in Pseudomonas aeruginosa-positive surveillance cultures after implementation of these measures...
  97. ncbi Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, Bologna, Italy
    Stem Cells 24:2817-25. 2006
    ....